Skip to main content

Drug Interactions between aminocaproic acid and tenecteplase

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

aminocaproic acid tenecteplase

Applies to: aminocaproic acid and tenecteplase

MONITOR: Coadministration of an antifibrinolytic agent (e.g., aminocaproic acid, tranexamic acid, aprotinin) in combination with a tissue plasminogen activator (t-PA) may reduce the therapeutic effects of both drugs due to opposing pharmacodynamic actions. Aminocaproic acid and tranexamic acid are competitive inhibitors of plasminogen activation. At high concentrations they can also directly inhibit plasmin, which is needed for the degradation of fibrin and thrombolysis. Aprotinin is a broad-spectrum protease inhibitor that inhibits plasmin. It is known to have antifibrinolytic activity and may interact with t-PAs in a similar fashion.

MANAGEMENT: No specific intervention is warranted, but clinicians should be alert to the potential for diminished therapeutic efficacy if a tissue plasminogen activator is administered to a patient who has been treated with an antifibrinolytic agent, and vice versa.

References (4)
  1. (2001) "Product Information. Trasylol (aprotinin)." Bayer
  2. (2001) "Product Information. Amicar (aminocaproic acid)." Immunex Corporation
  3. (2001) "Product Information. Cyklokapron (tranexamic acid)." Pharmacia and Upjohn
  4. (2022) "Product Information. Lysteda (tranexamic acid)." Xanodyne Pharmaceuticals Inc

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer